Teva Pharmaceutical Industries (TEVA) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 28, 2026, in a virtual-only format at 4:00 p.m. Israel time / 9:00 a.m. Eastern time.

• Proxy materials, including the proxy statement and annual report, are available online, with options for shareholders to request paper or email copies by May 7, 2026.

• Shareholders must be on record as of April 6, 2026, to vote at the meeting.

Voting matters and shareholder proposals

• Proposal 1: Appointment of Dr. Sol J. Barer as director until the 2029 annual meeting.

• Proposal 2: Advisory vote to approve compensation for named executive officers.

• Proposal 3: Appointment of Kesselman & Kesselman (PwC) as independent auditor until the 2027 annual meeting.

• Board recommends voting FOR all proposals.

• Shareholders will also consider annual consolidated financial statements for the year ended December 31, 2025.

Board of directors and corporate governance

• Board recommends the reappointment of Dr. Sol J. Barer as director for a term ending at the 2029 annual meeting.